201.22 USD
↗ 4.70 (2.39%)AT CLOSE (11:59 AM EDT)
Jazz Pharmaceuticals, Inc.
JAZZNASDAQ • USD
201.31
↗ 0.09 (0.04%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
201.31
↗ 0.09 (0.04%)
Market: CLOSED
Open?$198.16
High?$204.52
Low?$198.16
Prev. Close?$196.52
Volume?1.3M
Avg. Volume?921.4K
VWAP?$202.56
Rel. Volume?1.42x
Bid / Ask
Bid?$196.52 × 100
Ask?$207.00 × 100
Spread?$10.48
Midpoint?$201.76
Valuation & Ratios
Market Cap?12.4B
Shares Out?61.6M
Float?59.3M
Float %?96.4%
P/E Ratio?N/A
P/B Ratio?2.87
EPS?-$5.79
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.86Adequate
Quick Ratio?1.67Adequate
Cash Ratio?0.62Adequate
Debt/Equity?1.24Moderate
ValuationATTRACTIVELY VALUED
Score87/100
P/E?N/A▾
P/B?2.87CHEAP▾
P/S?2.90CHEAP▾
P/FCF?9.6CHEAP▾
EV/EBITDA?13.5FAIR▾
EV/Sales?3.83FAIR▾
Returns & Efficiency
ROE?-8.3%WEAK▾
ROA?-3.1%WEAK▾
Cash Flow & Enterprise
FCF?$1.3B
Enterprise Value?$16.4B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Employees
2.9K
Market Cap
12.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2007-06-01
Address
FIFTH FLOOR, WATERLOO EXCHANGE
DUBLIN, D04 E5W7
Phone: 353-1-634-7800
DUBLIN, D04 E5W7
Phone: 353-1-634-7800